Alnylam Pharmaceuticals
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- $35.9B
- Website
- http://www.alnylam.com/
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT04565717
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Recruiting
- Conditions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT04561518
- Locations
- π¨π³
Clinical Trial Site, Taipei, Taiwan
A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 67
- Registration Number
- NCT04201418
- Locations
- πΊπΈ
Clinical Trial Site, Milwaukee, Wisconsin, United States
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 655
- Registration Number
- NCT04153149
- Locations
- π¬π§
Clinical Trial Site, Middlesbrough, United Kingdom
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT04152200
- Locations
- π¦πͺ
Clinical Trial Site, Dubai, United Arab Emirates
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
- Conditions
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Alnylam Pharmaceuticals
- Registration Number
- NCT04125472
Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria
- Conditions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Alnylam Pharmaceuticals
- Registration Number
- NCT04056481
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 360
- Registration Number
- NCT03997383
- Locations
- π¬π§
Clinical Trial Site, Stockton-on-Tees, United Kingdom
A Study to Evaluate ALN-AGT01 in Patients With Hypertension
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT03934307
- Locations
- π¬π§
Clinical Trial Site, Manchester, United Kingdom
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03905694
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
Β© Copyright 2024. All Rights Reserved by MedPath